AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05209451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital, evidence-based behavioral health program for smoking cessation
Description: Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
Study NCT05209451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bluetooth enabled iPad
Description: Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
Study NCT05209451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching Support
Description: Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
Study NCT06607250 — intervention group
Intervention type: RADIATION
Intervention: MRI
Description: All enrolled patients underwent multiparametric magnetic resonance imaging, encompassing T2-weighted imaging (T2WI) and magnetic resonance diffusion-weighted imaging (DWI), in the coronal, sagittal, and axial planes.
Study NCT06606392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex balance system
Description: The Biodex Balance System has a wide range of clinical applications and provides objective measures from testing that can be used to establish progressions and discharge criteria, as well as be part of a comprehensive Fall Risk Assessment or Fall Screening Program. Balance ability can be assessed either statically or dynamically, as well as bilaterally and unilaterally. It also allows for bilateral comparisons between involved and uninvolved limbs.
Study NCT06606392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Short Foot Exercise
Description: Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
Study NCT06606392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Foot Exercise
Description: Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
Study NCT06608446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session.
Study NCT06608446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
Study NCT06607562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
Study NCT06607562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
Study NCT06608342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation combined with CD19-CART
Description: Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
Study NCT06264817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBIDERM Autofit Armsleeve
Description: In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks
Study NCT06264817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compressive bandaging
Description: In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks
Study NCT06677164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gluteus Maximus strengthening exercise
Description: Maximus strengthening exercise for eight weeks using weight progression tools either elastic band or sand weight by assuming two modes of exercises (clamshell exercise, prone hip extension) with stretching exercise (hamstring, gastrocnemius, soleus, and plantar fascia) 2 sessions per week for 8 weeks
Study NCT06677164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser therapy
Description: A 3-phase treatment program will be performed in each session on the plantar fascia area. Treatment of trigger points in phase 1 and 2 by using power of 9 watts, E2C mode for 6 minute of 2 phases. The draining and vascularization-promoting application involve the whole foot sole, starting from the heel area in phase three by using power of 9 watts, CW mode with energy of 100J/cm2.
Study NCT06677164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser therapy
Description: A 3-phase treatment program will be performed in each session on the plantar fascia area. Treatment of trigger points in phase 1 and 2 by using power of 9 watts, E2C mode for 6 minute of 2 phases. The draining and vascularization-promoting application involve the whole foot sole, starting from the heel area in phase three by using power of 9 watts, CW mode with energy of 100J/cm2.
Study NCT06483256 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: radiographic control
Description: Radiographic study with standard projections (AP and LL) is used to assess any signs of anchor loosening and/or presence of heterotopic ossifications (which can restrict movement and is one of the main complications).
Study NCT06315179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Esophagogastroduodenoscopy (EGD) with biopsy
Description: Esophagogastroduodenoscopy (EGD) is a test procedure to examine the lining of the esophagus, stomach, and first part of the small intestine.
Study NCT06040099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV (intravenous)
Study NCT06040099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Radioembolization (TARE)
Description: Yttrium 90 glass microspheres will be administered
Study NCT06109467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
Study NCT06109467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
Study NCT06109467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
Study NCT06109467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil + leucovorin
Description: All participants will receive 400 mg/m\^2 5-Fluorouracil (5FU)+ 400 mg/m\^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
Study NCT05473338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool and blood samples
Description: fecal microbiome and metabolomics, as well as metabolites in plasma
Study NCT05473338 — intervention group
Intervention type: OTHER
Intervention: Physical examination
Description: physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
Study NCT05473338 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires measuring pain level, sleep, mood and diet parameters.
Study NCT06109467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
Study NCT06647069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bispecific antibody
Study NCT05792371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induced membrane technique
Description: Masquelet technique, also called an induced membrane technique (IMT), was first introduced to treat critical size bone defect up to 25 cm in 1986 by Pr. Alain Charles Masquelet et al. IMT is a two-stage surgical operation that recently provides a more popular option for the treatment of critical size bone defect as well as fracture nonunion. Basically, first stage of IMT comprises the implantation of a polymethylmethacrylate (PMMA) cement spacer loaded with antibiotics into defect site. During 6 to 8 weeks, this spacer induces the formation and maturation of a thin layer called induced membrane surrounding it via a foreign body immune response. In stage II, the spacer is carefully removed while keeping induced membrane at the fracture site, autologous bone graft is then performed to provoke bone healing.
Study NCT05792371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone graft (Stage II of IMT)
Description: Bone graft is only performed in this group to provoke bone healing, as same as demonstrated in the stage II of IMT.
Study NCT04130126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking cold showers
Description: Showering behaviour
Study NCT06045026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stannous fluoride
Description: Anti-sensitivity toothpaste containing 0.454% Stannous Fluoride
Study NCT05516706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic stretching
Description: Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
Study NCT05516706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric push up
Description: Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
Study NCT05486468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yutiq 0.18 MG Drug Implant
Description: YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
Study NCT05486468 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham injection
Study NCT04880512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX 1901 tablets
Description: SYHX 1901, oral tablets, in fasted state
Study NCT04880512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, oral tablets, in fasted state
Study NCT04782089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors
Description: Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
Study NCT05251909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
Study NCT05251909 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
Study NCT06346990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holy Quran Recital
Description: Holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each
Study NCT06315179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy w/ biopsy
Description: Colonoscopy is a test procedure to examine the lining of the different portions of the large intestine: cecum, colon, rectum, and anal canal.
Study NCT06608043 — intervention group
Intervention type: BEHAVIORAL
Intervention: Reborn lifestyle adjustment program
Description: The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules.
Study NCT06608043 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional Physiotherapy and Occupational Therapy
Description: Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
Study NCT06689956 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT06037941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: E-Nose testing
Description: At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
Study NCT06037941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Research blood
Description: Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
Study NCT06706076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH-30643
Description: BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment.
Study NCT06761690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid simulated wound training
Description: hybrid simulated wound training
Study NCT06762262 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Moderate-Intensity continuous training
Description: refers to a type of aerobic exercise that involves maintaining a steady and moderate level of physical activity for an extended period. The exercise is performed at a consistent and moderate pace without significant fluctuations in intensity. MICT primarily targets the aerobic energy system, enhancing cardiovascular endurance and respiratory efficiency
Study NCT06762262 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity continuous training
Description: refers to a type of aerobic exercise that involves maintaining a steady and moderate level of physical activity for an extended period. The exercise is performed at a consistent and moderate pace without significant fluctuations in intensity. MICT primarily targets the aerobic energy system, enhancing cardiovascular endurance and respiratory efficiency
Study NCT06237452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VE303
Description: VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.
Study NCT06237452 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.
Study NCT06760533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25 mg
Description: Psilocybin 25 mg (active treatment) administered during the psychotherapy treatment session.
Study NCT06760533 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy Treatment Session
Description: The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.
Study NCT06760533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy Treatment Session
Description: The psychotherapy treatment sessions will be conducted by two therapists, who will be both present for all the sessions during three phases of treatment: Preparation, Medication Administration, and Integration.
Study NCT06760533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin 100 mg
Description: Niacin 100 mg (placebo) administered during the psychotherapy treatment session.
Study NCT06761586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR104
Description: Once or twice a day
Study NCT06762249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT + Brunnstrom therapy + routine physical therapy
Description: this therapy will be given for 5 days per week for 4 weeks.
Study NCT06762249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CIMT + routine physical therapy
Description: this therapy will be given for 5 days per week for 4 weeks
Study NCT06761339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Azka Nasal and Throat for Children
Description: Azka Nasal and Throat for Children is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in pediatric patients. The intervention involves administering 7.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days. The supplement is intended to alleviate symptoms of nasal and throat irritation, reduce phlegm, and improve overall respiratory comfort. Azka Nasal and Throat for Children has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in pediatric respiratory care.
Study NCT06761339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prospan cough Syrup
Description: The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.
Study NCT06761846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Chemotherapy
Description: chemotherapy includes SOX and XELOX
Study NCT06028178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Droplet digital PCR
Description: Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
Study NCT05704140 — intervention group
Intervention type: OTHER
Intervention: Catheter based Dialysis
Description: We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.